S'abonner

Prognostic indicators in venous ulcers - 05/09/11

Doi : 10.1067/mjd.2000.107496 
Tania J. Phillips, MD a, Fidelis Machado, MD b, Richard Trout, PhD c, John Porter, MD d, Jeffrey Olin, MD e, Vincent Falanga, MD a

The Venous Ulcer Study Group*

Boston, Massachusetts; Princeton and Piscataway, New Jersey; Portland, Oregon; and Cleveland, Ohio 
From the Department of Dermatology, Boston University School of Medicinea; Convatec, Inc, Princetonb; statistical consultant, Piscatawayc; the Department of Vascular Surgery, Oregon Health Sciences Universityd; and the Department of Vascular Medicine, The Cleveland Clinic Foundation.e 

Abstract

Background: Venous ulcers can be difficult to heal, and prognostic factors for healing have not been fully elucidated. Objective: The objective of this study was to analyze the results of a large multicenter venous ulcer trial to retrospectively establish prognostic factors for venous ulcer healing. Methods: This study examined data from a previously published prospective randomized placebo-controlled trial of an oral medication versus placebo treatment for venous ulcers. Local leg ulcer care involved the use of a moisture-retentive dressing and sustained graduated compression with a paste bandage and a self-adherent wrap. The oral medication or placebo was administered on a daily basis with the same dressings and bandage system in both groups for 12 weeks. A total of 165 patients completed the full 12-week treatment period; 83 received ifetroban, 82 received placebo. Results: There was no statistically significant difference in outcome between the two groups. The study showed that consistent local ulcer treatment with a clearly defined system of care was associated with an unexpectedly high percentage (55%) of long-standing large venous ulcers (mean duration, 27 months; mean area, 15.9 cm2) being healed in both groups. Baseline ulcer area and duration of leg ulcer were found to be important in predicting outcome. Ulcers of short duration were found to be most likely to heal. Percent healing and ulcer area at week 3 were good predictors of 100% healing. Ulcers that had at least 40% healing by week 3 predicted more than 70% of the outcomes correctly. Conclusion: From this large study it was determined that baseline ulcer area and ulcer duration are significant predictors of 100% healing and time to heal. Percent healing and ulcer area at week 3 are good predictors of complete ulcer healing. Ulcers that are large, long-standing, and slow to heal after 3 weeks of optimal therapy are unlikely to heal rapidly, and might benefit from alternative therapies. (J Am Acad Dermatol 2000;43:627-30.)

Le texte complet de cet article est disponible en PDF.

Plan


 Sponsored by Bristol Myers Squibb, PRI.
 Reprint requests: Fidelis Machado, MD, 200 Headquarters Park Dr, Skillman, NJ 08558.
 *Members of The Venous Ulcer Study Group are given at the end of this article.
 J Am Acad Dermatol 2000;43:627-30.


© 2000  American Academy of Dermatology, Inc. Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 43 - N° 4

P. 627-630 - octobre 2000 Retour au numéro
Article précédent Article précédent
  • Sensitivity and specificity of clinical, histologic, and immunologic features in the diagnosis of paraneoplastic pemphigus
  • P. Joly, C. Richard, D. Gilbert, P. Courville, O. Chosidow, J.C. Roujeau, M. Beylot-Barry, M. D'Incan, Ph. Martel, Ph. Lauret, F. Tron, The members of the French Study Group on bullous diseases*
| Article suivant Article suivant
  • Raynaud's phenomenon, anticentromere antibodies, and digital necrosis without sclerodactyly: An entity independent of scleroderma?
  • Evelyn M. Sachsenberg-Studer, Christa Prins, Jean-Hilaire Saurat, Denis Salomon

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.